Compared to our previous studies [16,19], nine additional histopathologically confirmed IDH mutant glioma patients were recruited in this follow-up study, as well as one more patient showing a visually discernible 2-HG peak at 2.25 ppm but who declined surgery and therefore remains without histopathological diagnosis. The gene discussed is IDH2; the disease is central nervous system cancer.